Carlos Lopez, MD
Family Medicine · Phoenix, AZNPI 1952309320
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by GSK at 42.5% of the total. Reporting peaked in 2023 at $509 and has fallen 53.3% since, to $238 in 2025.
Across 60 payments — averaging $29.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$750
- Merck$201
- Cranial Technologies, Inc$171
- Novartis$170
- Pfizer$128
- Exact Sciences$80
- plus $265 from 9 others
Across 54 payments — averaging $4118.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$89K
- GSK$63K
- Modernatx, Inc.$36K
- AstraZeneca$35K
What the payments were for
- Food & beverage$1,75499%
- Education$111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $750 |
| Merck | 5 | $201 |
| Cranial Technologies, Inc | 11 | $171 |
| Novartis | 2 | $170 |
| Pfizer | 6 | $128 |
| Exact Sciences | 4 | $80 |
| Sanofi Pasteur Inc. | 3 | $55 |
| Novo Nordisk | 3 | $55 |
| Boston Scientific | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Abbott | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEXSERO$375
- VAXNEUVANCE$123
- SHINGRIX$116
- XOLAIR$112
How this compares
$1,764 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 17 | $378 |
| Atorvastatin Calcium | 14 | $292 |
| Amlodipine Besylate | 18 | $245 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Phoenix
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Heather ElwoodPhoenix$236K
- Ahmed AghaPhoenix$92K
- Valerie MirandaPhoenix$91K
- Randy GelowPhoenix$56K
- Gabrielle GoodrickPhoenix$32K
- Trisha TavaresPhoenix$32K
- Donald MulvaneyPhoenix$21K
- Carlos GarretonPhoenix$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.